Sanofi bags Scil's arthritis and cartilage program
Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up to EUR180m in upfront and potential milestone payments. Moreover, the Bavarians are entitled to undisclosed royalties on worldwide product sales. Sanofi will take over from day one, including the start of clinical trials. "Sanofi's profound expertise in the therapeutic area make us confident, that they are the right partner we could find for this programme" said Scil's COO Klaus Binder.
The programme is based on targets for the regeneration of cartilage tissue, which also stimulate chondrocyte differentiation and the synthesis of cartilage matrix. The leading compound is based on a proprietary formulation for direct delivery into the joint, making it an excellent treatment option for osteoarthritis. The programme is currently in preclinical development.
The cartilage regenerative program is Scil Technology’s second programme which has been out-licensed. The first (GDF-5) was taken over by Medtronic after completion of Phase II trials. And in 2008, U.S. Pfizer obtained a worldwide exclusive license to develop and commercialise CD- RAP, Scil's cartilage specific growth factor.